Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas (EPNC)

This review notes the introduction of immune checkpoint inhibitors signifies the first new systemic treatment option for small cell lung cancer in decades. Patients with EPNC need to be included in clinical trials to prove the value of these and other new drugs for these patients

JAMA Oncology